Circadian Dysregulation of the TGFβ/SMAD4 Pathway Modulates Metastatic Properties and Cell Fate Decisions in Pancreatic Cancer Cells by Li, Yin et al.
ll
OPEN ACCESSiScience
ArticleCircadian Dysregulation of the TGFb/SMAD4
Pathway Modulates Metastatic Properties and Cell









































exists between the TGFb
pathway and the circadian







PDA cells shows time- and
SMAD4-dependent
effects
Li et al., iScience 23, 101551





OPEN ACCESSiScienceArticleCircadian Dysregulation of the TGFb/SMAD4
Pathway Modulates Metastatic Properties and Cell
Fate Decisions in Pancreatic Cancer Cells
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Impairment of circadian rhythms impacts carcinogenesis. SMAD4, a clock-
controlled gene and central component of the TGFb canonical pathway, is
frequently mutated in pancreatic ductal adenocarcinoma (PDA), leading to
decreased survival. Here, we used an in vitro PDA model of SMAD4-positive
and SMAD4-negative cells to investigate the interplay between circadian
rhythms, the TGFb canonical signaling pathway, and its impact on tumor malig-
nancy. Our data show that TGFb1, SMAD3, SMAD4, and SMAD7 oscillate in a
circadian fashion in SMAD4-positive PDA cells, whereas altering the clock impairs
the mRNA dynamics of these genes. Furthermore, the expression of the clock
genes DEC1, DEC2, and CRY1 varied depending on SMAD4 status. TGFb
pathway activation resulted in an altered clock, cell-cycle arrest, accelerated
apoptosis rate, enhanced invasiveness, and chemosensitivity. Our data suggest
that the impact of TGFb on the clock is SMAD4-dependent, and SMAD3,
SMAD4, DEC1, and CRY1 involved in this cross-talk affect PDA patient survival.
INTRODUCTION
In mammals, an internal biological timing system, the circadian clock coordinates the time of behavioral
activities and physiological processes. At the molecular level, the circadian clock is composed of a set of
genes and their protein products, interconnected by transcriptional/translational feedback loops (Fuhr
et al., 2015). This core-clock network (CCN) generates endogenous 24-h oscillations in the expression of
genes and proteins and is involved in the circadian regulation of various cellular processes, including
the cell cycle (El-Athman et al., 2017), apoptosis (Gery et al., 2005; Wang et al., 2016), DNA repair (Di Micco
et al., 2011), the epithelial-to-mesenchymal transition (EMT) (Mao et al., 2012), metabolism (Fuhr et al.,
2018; Reinke and Asher, 2019), and immunity (Abreu et al., 2018). Its aberrant function impacts cell func-
tioning and can lead to the development and progression of several diseases including cancer (Davis
et al., 2019; Sulli et al., 2019; Yalcin et al., 2020). Genes involved in cell cycle regulation (e.g., MYC,
WEE1, and INK4A), immune function (e.g., TNF), and metabolism (e.g., SIRT3, CPT1, and PDH) show a
rhythmic pattern of expression and are known clock-controlled genes (CCGs).
The transforming growth factor b (TGFb) transduction pathway is among the clock-controlled pathways
involved in oncogenic transformation. The TGFb pathway is implicated in the maintenance of tissue ho-
meostasis, regulation of fetal development, immune system control, wound repair, and EMT (Massague,
2008). The basic elements of the canonical TGFb pathway include TGFb cytokines, receptors, and Smads
(Smad4, receptor-Smads, and inhibitory-Smads). TGFb activates downstream pathways by binding to
two pairs of receptors (type I and type II receptors). Once the receptors are activated, reporter-Smads
(R-Smads) undergo phosphorylation, which results in signal propagation. The activated R-Smads (Smad2
and Smad3) translocate to the nucleus and form a complex with Smad4. Activated Smad complexes regu-
late gene expression by DNA-binding activity, and inhibitory-Smads (Smad7) prevent this complex forma-
tion (Massague, 2008; Prunier et al., 2019).
In normal and premalignant cells, TGFb functions as tumor suppressor via the regulation of cytostasis, dif-
ferentiation, cell cycle, apoptosis, and suppression of inflammation, andmalfunctions in the TGFb signaling
pathway can result in tumorigenesis (Cheng et al., 2001; Massague, 2008; Principe et al., 2017; Scandura
et al., 2004; Siegel and Massague, 2003).iScience 23, 101551, October 23, 2020 ª 2020 The Authors.





ArticlePancreatic ductal adenocarcinoma (PDA) is amalignant diseasewithpoor prognosis and lowoverall survival rate,
and it is the fourth leading cause of cancer death in the European Union and the United States (Coveler et al.,
2016). More than half of the patients with PDA harbormutations in SMAD4. The inactivation of SMAD4 in tumors
is a common event in advanced-stage PDA and is linked to poorer prognosis (Singh et al., 2012).
Interestingly, several components of the TGFb canonical pathway are circadian regulated in different organisms
(Akagi et al., 2017; Chen et al., 2015; Sato et al., 2019). Previous studies reported circadian expression of TGFb1
and Smad3 (transcripts or proteins) in mouse brown adipocyte (Nam et al., 2015), mouse kidney (Sato et al.,
2019), and mouse heart (Sato et al., 2017). In addition, the oscillating pattern of TGFb1 was altered after the
disruption of Clock (Chen et al., 2015). However, it remains unclear whether components of the TGFb canonical
signaling (including TGFb1, SMAD4, SMAD3, and SMAD7) are clock regulated in human cancer cells and
whether circadian disruption affects these elements in cancer cells with consequences on tumor malignancy.
Work from our group indicates that Smad4, the coremediator of the TGFb canonical pathway, is regulated indi-
rectly by the circadian clock (Lehmann et al., 2015). Wu et al. reported the binding of Smad3 or Smad4 to the
Smad-binding elements in the DEC1 promoter in pancreatic cancer cells, further contributing to their circadian
regulation (Wu et al., 2012). These studies pointed to a link bridging the circadian and TGFb pathway.
Despite current findings regarding rhythmicity in elements of the TGFb pathway and the functionality of this
pathway, the reciprocal interplay between the TGFb/SMAD4 pathway, the circadian clock, and its impact
on tumor progression remains unclear in PDA.
Here, we investigated the influence of a dysregulated biological clock on PDA progression using an in vitro
cellular model system. For this, we used SMAD4 wild-type and mutant PDA cell lines, derived respectively,
from the primary tumor and the metastatic lesions of patients with PDA. We further explored the impact of
clock dysregulation on the TGFb/SMAD4 canonical pathway. Our results show that elements of the TGFb
canonical pathway (including SMAD3, SMAD4, SMAD7, and TGFb1) are expressed in a circadian manner in
SMAD4 wild-type PDA cells. In addition, we found that the rhythmic expression of the above-mentioned
transcripts was altered upon the dysregulation of the circadian clock, suggesting that these TGFb canonical
elements are under circadian modulation. Our data point to a modulation of the TGFb canonical pathway
via the clock through interactions with the transcription factors DEC1, DEC2, and the core-clock gene
CRY1. Also, we explored the influence of the canonical TGFb pathway on the clock phenotype in these cells.
Our results indicated that the activation of the TGFb canonical pathway through SMAD4 overexpression
and TGFb induction results in a faster clock in PDA cells. Also, genetic modifications of SMAD4 (knockdown
or overexpression) altered the expression of the core-clock genes BMAL1, PER2,NR1D1, and CRY1, and of
the clock- and TGFb-controlled genes, DEC1 and DEC2.
Furthermore, we investigated proliferation, apoptosis, migration, and invasion in clock-disrupted
(shBMAL1, shPER2, and shNR1D1 knockdown) and SMAD4 up- or downregulated PDA cells, as well as
the effects of a dysregulated clock on drug sensitivity in both SMAD4-proficient and SMAD4-deficient
PDA cell lines. Our data provide evidence for SMAD4- and clock-dependent drug response in PDA cells,
and highlight the role of the bidirectional interaction between the biological clock and the TGFb/
SMAD4 canonical pathway in cell cycle, apoptosis, and cancer metastasis in pancreatic cancer cells, which
may further affect patient survival.RESULTS
Bidirectional Interplay between the Circadian Clock and TGFb Canonical Pathway
To investigate the impact of a dysregulated clock in cancer metastasis and cell fate decisions in a pancre-
atic cancer cellular model, we used an established in vitromodel of SMAD4-proficient (Panc1) and SMAD4-
deficient (AsPC1) pancreatic adenocarcinoma cells (PDA), derived fromdifferent anatomical patient lesions
(primary tumor and metastasis ascites, respectively) representing PDA tumors at different stages. Panc1
(ATCC: CRL-1469) is derived from the primary tumor of a male patient. The cell line AsPC1 (ATCC: CRL-
1682) was established from ascites of a female patient with PDA. The doubling time of both cell lines is
very similar and close to 52 h (Lieber et al., 1975; Watanabe et al., 2012). In addition, we analyzed cell growth
of wild-type Panc1 and AsPC1 in our work using cell nucleus fluorescence labeling, which shows similar
growth curves within 72 h for both cell lines (nG SEM, n = 8, Figure S1D). Hence, both cell lines show similar
cell cycle dynamics, making them suitable for our study. Of note, both cell lines carry mutated forms of
















































































































































































































































Figure 1. Panc1 and AsPC1 Cell Lines Harbor Different Clock Phenotypes
(A) Panc1 and AsPC1 cells were lentivirally transduced with a BMAL1 promoter (green) or PER2 promoter (orange)-driven luciferase construct.
Bioluminescence was measured for 5 consecutive days. Depicted is one representative replicate for each condition.
(B) The 48 h time course RT-qPCR measurements of selected core-clock genes (BMAL1, PER2, and NR1D1) in Panc1 and AsPC1 WT cells.
(C) The relative mRNA levels of SMAD4 compared with AsPC1.
(D) RT-qPCR measurements after knockdown of core-clock genes (shBMAL1, shPER2, and shNR1D1) in Panc1 and AsPC1 cells.




Articlework for this study (via computational network analysis) showed that, among the highly mutated genes in
PDA (above 5% mutation rate), SMAD4 is tightly correlated with the CCN and has an impact on patient
outcome (Cancer Genome Atlas Research Network, 2017; Lehmann et al., 2015).
Both cell lines showed oscillations, but with smaller amplitudes and shorter period for the Panc1 cells
(BMAL1: 26.1 G 0.3 h, n = 3) when compared with the AsPC1 cells (BMAL1: 27.4 G 0.6 h, n = 3, Figure 1A).
The oscillation parameters of PER2:Luc are provided in Table 1. We performed a 48 h time course RT-qPCR
analysis, which confirmed the phenotypes observed in our luminescence data for BMAL1 and PER2 with an
anti-phasic oscillation in both PDA cells (Figures 1A and 1B, Tables 1 and 2). Thus, according to our data,
the endogenous time machinery operates differentially in these PDA cell lines.
Next, to explore the impact of clock disruption in the TGFb pathway, we produced knockdown PDA cell
lines for the core-clock genes BMAL1, PER2, andNR1D1 and evaluated the output in terms of gene expres-
sion (Figures 1D, S1B, and S1C). SMAD4 expression in Panc1 cells was significantly higher when compared
with that of AsPC1 (Figure 1C, ***p < 0.001). We confirmed that AsPC1 is a SMAD4-deficient cell line at the
protein level (Figure S1A), as previously reported (Schutte et al., 1996; Sun et al., 2001). Furthermore,
SMAD4 expression was downregulated in Panc1-shBMAL1 and Panc1-shNR1D1 cells at 3 h after cell syn-
chronization (Figure 1D, Panc1, **p < 0.01, n = 3). Interestingly, the downregulation of BMAL1 and NR1D1
impacts the rhythmic expression of SMAD4 in the SMAD4-proficient PDA cells (Figure 2A).
We further evaluated the consequences of these perturbations on the clock phenotype (Figure S2). The
downregulation of BMAL1 and PER2 in Panc1 cells resulted in an almost complete loss of oscillations,
whereas NR1D1 KD (knockdown) showed no significant effect on the rhythmicity of BMAL1. The downre-
gulation of BMAL1 in AsPC1 cells led to a complete loss of oscillations, and AsPC1-shNR1D1 cells depicted
a significant shorter period.
Our results point to a connection between core-clock elements and SMAD4. To further investigate this interplay,
we quantified the expression of SMAD3, SMAD4, SMAD7, and TGFb1 in our in vitro model (Figure S3).iScience 23, 101551, October 23, 2020 3
Panc1 AsPC1
Period (h) 26.6 G 2.7 26.4 G 0.4
Phase (h) 22.1 G 2.7 5.2 G 0.5
Amplitude 0.2 G 0.0 0.2 G 0.1
CC 0.9 G 0.1 0.9 G 0.1
Phase shift relative to BMAL1
(h)
15.0 6.8




ArticleAccording to previous studies in other model systems (Chen et al., 2015; Nam et al., 2015), Clock-Bmal1 hetero-
dimers or Bmal1 activate the expression of Tgfb, Smad3 by binding to their promoter regions. Particularly, the
robust circadian rhythmicity ofmTgfb1 is abolished inmClock-KOmice (Chen et al., 2015). Such findings suggest
the existence of a circadian regulation of these TGFb signaling components at the transcriptome level. Thereby,
we hypothesized that this phenomenonmight also exist in human PDA cancer cells. We found rhythmic expres-
sion of TGFb1 in both the SMAD4-proficient and SMAD4-deficient PDA cells (Figures S3A and S3E). Surprisingly,
we also observed circadian oscillations in the expression of SMAD3, SMAD4, and SMAD7 in SMAD4 WT cells
(Panc1, Figures S3B–S3D and Table 3). Interestingly, SMAD3 and TGFb1 transcripts oscillated with slightly
different phases and similar periods asBMAL1 in SMAD4-proficient cells (Panc1, Figure S3, Tables 2 and 3). How-
ever, the oscillation of TGFb1 exhibited longer periods (27 h) when compared with BMAL1 (22.3 G 0.9 h) in
SMAD4-deficient cells (AsPC1, Figure S3E), implying that the correlation between the rhythmic expression of
TGFb1 and BMAL1 is likely SMAD4 dependent. Furthermore, we compared the expression level of these com-
ponents for the PDA cell lines in a 39 h time course (Figures S3F–S3H). The mRNA levels of SMAD3 and SMAD7
(Figures S3G and S3H) were much reduced in AsPC1 when compared with Panc1, whereas TGFb1 was highly
expressed in AsPC1 when compared with Panc1 (Figure S3F). These data point to the inactivation of the
TGFb canonical pathway in SMAD4-deficient PDA cells, whichmay result in altered interactionwith the clockma-
chinery and ultimately support further progression towards malignant phenotypes.
We further explored the reciprocal interplay between the core-clock and the TGFb canonical pathway and
analyzed the effect of perturbing the core-clock elements on the expression of several components of the
TGFb canonical pathway (SMAD3, SMAD7, and TGFb1).
A former study suggested Bmal1 and Nr1d1 to be key clock elements bridging the clock and the TGFb ca-
nonical pathway in mouse adipocytes (Nam et al., 2015). Hence, we performed a 24 h time course RT-qPCR
for BMAL1 and NR1D1 KDs and shCtrl in Panc1 cells. The expression of TGFb1, SMAD3, SMAD4, and
SMAD7 exhibited a large variation after theBMAL1 andNR1D1 KDswhen comparedwith shCtrl (Figure 2A).
In particular, in Panc1-shBMAL1 and Panc1-shNR1D1 cells, the expression of SMAD4 reached its peak at
18 h after synchronization. As previously reported, Bmal1 binding to the promoter region of Smad3 (result-
ing in activation of Smad3) occurred at a specific time point (CT8 in mice) (Nam et al., 2015). Our results
show that clock dysregulation (BMAL1 KD) repressed SMAD3 and SMAD7 transcripts at 21 h after synchro-
nization, suggesting that the inactivation of the TGFb canonical pathway (particularly SMAD7 as an indica-
tor of the TGFb pathway activation) occurs at a specific time point after the clock disruption (Figure 2A). The
TGFb1 transcript was overexpressed upon BMAL1 KD over the time of the measurements (Figure 2A).
These data indicated that the disruption of BMAL1 and NR1D1 modified the time-dependent variations
of elements of the TGFb pathway (Figures 2A and S3). We observed a similar expression pattern of
SMAD3 and SMAD7 upon BMAL1 and NR1D1 KDs, indicating that these elements may assist to set up a
rapid reciprocal cross-talk between the TGFb canonical pathway and the circadian clock (Figure 2A).
We then measured BMAL1- and PER2-promoter activity in SMAD4-KD and overexpression (SMAD4-OE)
cells when compared with the corresponding control conditions (shCtrl or oeCtrl) and with additional
TGFb1 stimulation, to explore the impact of the TGFb pathway on the clock phenotype. Overexpression
efficiency was analyzed at the transcript and protein levels (Figure S5A and S5B). The activation of the
TGFb canonical pathway by SMAD4-OE and additional TGFb1 stimulation significantly shortened the




Phase (h) 17.0 G 0.5 4.1 G 0.7 14.4 G 0.5
Period (h) 19.0 G 1.0 18.3 G 1.5 18.6 G 0
Amplitude 0.2 G 0.1 0.2 G 0.1 0.1 G 0.1
p Value <0.0001 <0.0001 0.045
AsPC1
BMAL1 PER2 NR1D1
Phase (h) 14.4 G 0.3 0 G 3.6 20 G 0.0
Period (h) 22.3. G 0.9 24.8 G 0.0 20.0 G 1.3
Amplitude 0.3 G 0.0 0.2 G 0.1 0.2 G 0.1
p Value <0.0001 <0.0001 0.0003





Articlein Panc1 led to a shorter period when compared with shCtrl (Figures 2B and 2C, **p < 0.01), pointing to a
putative role of SMAD4 in the regulation of the circadian clock via BMAL1.
In addition, we evaluated the impact of SMAD4 in the regulation of core-clock elements BMAL1, PER2,
NR1D1, and CRY1 and further analyzed the expression of the clock genes DEC1 and DEC2 (Figures 2D,
2G, and 2J), reported as mediators in the above cross-talk (Kon et al., 2008; Sato et al., 2016, 2019). Inter-
estingly, most of the core-clock genes showed significant alterations for Panc1 SMAD4-OE and SMAD4-KD
(Figures 2D and 2G). Overall, CRY1 was upregulated, whereas DEC1 and DEC2 were downregulated in
SMAD4-OE PDA cells (Figures 2D and 2J, *p < 0.05, **p < 0.01, ***p < 0.001, n = 3). In agreement, we
observed the opposite results in Panc1-shSMAD4 (Figure 2G, **p < 0.01, ***p < 0.001, n = 3). These results
further reinforce the existence of a bidirectional connection between the core-clock and the SMAD4-
dependent pathways via the regulation of CRY1, DEC1, and DEC2.Dysregulation of the Core-Clock Genes BMAL1, PER2, and NR1D1, and Perturbations in
SMAD4 Impact Cell Proliferation and Apoptosis in PDA Cells
We further evaluated the effects of disrupting core-clock genes and SMAD4 in cell fate decisions by
analyzing cell proliferation and apoptosis. Interestingly, SMAD4-proficient (Panc1) and SMAD4-deficient
(AsPC1) cells showed different effects on proliferation upon the different knockdowns (Figure 3A). Prolifer-
ation increased in Panc1 cells after BMAL1 andNR1D1 KDs, whereas this was not observed in AsPC1 knock-
down cells (Figure 3A). Panc1-shSMAD4 cells showed increased proliferation when compared with the
shCtrl. However, SMAD4-OE in both PDA cells showed no significant difference in the proliferative ability
compared with oeCtrl. These results indicate that the non-canonical pathway (which includes RAS, MAPK,
JNK) might be activated after SMAD4 KD, leading to an increase in proliferation. To verify our assumption,
we measured RAS and phosphorylated-ERK (p-ERK) proteins in Panc1-shCtrl and Panc1-shSMAD4 cells
with and without a 24-h TGFb1 stimulation. Our results show that the TGFb1 stimulation activates the phos-
phorylation of ERK for both Panc1-shCrtl and Panc1-shSMAD4 (Figures S6A and S6C). In addition, SMAD4-
KD (particularly stimulated with TGFb1) indeed upregulated the expression of RAS and p-ERK, when
compared with control cells (Figures S6A–S6C). These data suggest the activation of the Ras pathway after
the downregulation of SMAD4. In addition, the apoptotic profiles of PDA cells were altered upon core-
clock dysregulation. The downregulation of BMAL1, PER2, and NR1D1 increased apoptosis when
compared with shCtrl (Figures 3B, 3C, and 3E). SMAD4OE promoted apoptosis in both PDA cells (Figures
3B, 3D, and 3F). These results implied that the upregulation of SMAD4 and the disruption of core-clock
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Figure 2. Panc1 and AsPC1 Cells as a Model for Investigating the Cross-Talk between the Circadian Clock and the TGFb Canonical Pathway
(A) The 24 h time course RT-qPCR was carried out in Panc1 cells (A) containing shCtrl empty vector, shBMAL1, and shNR1D1 constructs. Relative expression
value of TGFb signaling-associated genes (SMAD4, TGFb1, SMAD3, and SMAD7) is shown compared with shCtrl cells at each time point.
(B, C, E, F, H, and I) SMAD4-KD or SMAD4-OE cells were lentivirally transduced with a BMAL1- or a PER2-promoter-driven luciferase construct.
Bioluminescence was measured for 5 consecutive days with TGFb1 or corresponding empty vehicle (0.1% BSA). Depicted are the periods for Panc1 (B, C, E,
and F) and for AsPC1 (H and I) of BMAL1 or PER2 promoter activities, as indicated. One representative replicate for each condition is provided in Figure S4.
(D, G, and J) Effect of SMAD4-KD or SMAD4-OE on the expression of clock genes in Panc1 (D and G) and AsPC1 (J) cells.
Data are expressed as mean G SEM, n = 3, one-way ANOVA (B, C, E, F, H, and I) or multiple t test (D, G, and J); *p < 0.05, **p < 0.01, ***p < 0.001. See also




ArticleClock Dysregulation and the Activation of the TGFb/SMAD4 Pathway Impacts Apoptosis and
Cell Cycle in PDA Cells
To further characterize the putative effects of dysregulating the TGFb/SMAD4 signal transduction in our
model, we stimulated the pathway with TGFb1 in addition to SMAD4-KD or SMAD4-OE and analyzed
cell proliferation and apoptosis. The activation of the pathway (SMAD4-OE with TGFb1 stimulation) did
not alter proliferation in Panc1 cells, and its inactivation (SMAD4-KD with or without TGFb1) promoted pro-
liferation (Figures 4A and 4B). Interestingly, we observed increased proliferation in SMAD4-deficient cells
(AsPC1) with TGFb1 stimulations compared with SMAD4-OE cells (Figure 4C). Thus, we hypothesized that
TGFb1 triggers the downstream elements of the TGFb non-canonical signaling pathway (e.g., RAS, PI3K)
leading to increased proliferation in SMAD4-deficient cells.
The stimulation of TGFb1 induced apoptosis particularly in SMAD4-positive PDA cells (including SMAD4-
OE and wild-type, Figures 4E–4G).6 iScience 23, 101551, October 23, 2020
Cosinor Analysis
Panc1
TGFb1 SMAD3 SMAD7 SMAD4
Phase (h) 1.7 G 1.5 19.1 G 0.8 11.85 G 1.3 12.6 G 1.1
Period (h) 20.0 G 3.8 21.8 G 2.6 22.8 G 4.7 21.7 G 3.4
Amplitude 0.1 G 0.1 0.3 G 0.1 0.2 G 0.1 0.3 G 0.2
p Value 0.0015 0.0004 0.0001 0.0256
AsPC1
TGFb1
Phase (h) 4.6 G 0.3
Period (h) 27.0
Amplitude 0.2 G 0.0
p Value <0.0001
Table 3. Circadian Parameters Retrieved with Cosinor Analysis for a 33 h Time Course RT-qPCR Data (TGFb1,




ArticleWe analyzed the cell cycle of the PDA cells in greater detail in all the aforementioned conditions. Our
analysis showed significant cell-type-specific alterations upon KD of clock genes when compared with con-
trol cells. For the SMAD4-proficient cell line (Panc1), the percentage of cells in S phase decreased signifi-
cantly and G2/M phase increased after PER2 KD (Figure 4I, **p < 0.01, ***p < 0.001, n = 3), whereas the
percentage of cells in S phase increased after NR1D1, in agreement with the proliferation results. In
AsPC1 cells, we observed a significant increase of S phase and decrease of G1 phase in PER2 KD cells (Fig-
ure 4K, **p < 0.01, ***p < 0.001, n = 3), and no significant alterations upon the KD of BMAL1 andNR1D1, in
agreement with our proliferation results (Figure 3A). The differential phenotypes observed might result
from the different genomic background of both cell lines (in particular the SMAD4 alteration) that subse-
quently impacts the circadian pathway, leading to an overall differential proliferative phenotype.
Next, we investigated the impact of TGFb on the cell cycle. Panc1 cells depicted increased G1/S arrest
upon TGFb1 stimulation (Figures 4D and S5C). Interestingly, unlike the impact of TGFb1 that has been re-
ported in previous studies for other model systems (Alexandrow and Moses, 1995; Mukherjee et al., 2010),
and also found in SMAD4-proficient cells, a 24-h TGFb1 stimulation increased the percentage of cells in G2/
M phase in shNR1D1 cells (Figure S5C), pointing towards differential regulation of the cell cycle by TGFb
upon NR1D1 downregulation. Additional TGFb1 did not cause G1/S arrest in SMAD4-deficient cells
(AsPC1, Figures 4H and S5D); this is distinct from the observations in SMAD4-proficient cells (Panc1)
Instead, we observed an increase in G2/M or S phase in all KD conditions (shBMAL1, shPER2, and shNR1D1)
and shCtrl cells upon TGFb stimulation when compared with non-stimulated cells (Figures 4H and S5D).
These results point to a SMAD4 dependency regarding the effects of TGFb on cell cycle distribution.
We further analyzed the cell cycle in SMAD4-KD and SMAD4-OE conditions with or without additional
TGFb1 stimulation (Figures 4I–4K). For Panc1, the additional TGFb1 and upregulation of SMAD4 led to
increased number of cells in G1/S phase (Figures 4I and 4J). However, the impairment of the TGFb canon-
ical pathway (SMAD4 KD) increased the number of cells in S phase particularly when compared with the
activation of TGFb canonical pathway (shCtrlwith TGFb1): G1 decreased and S phase increased (Figure 4J).
In SMAD4-deficient cells (AsPC1), SMAD4 OE with additional TGFb1 stimulation resulted in an increased
G1 and decreased S phase when compared with oeCtrl cells (Figure 4K). However, in AsPC1 oeCtrl cells,
TGFb1 stimulation led to an increase in the percentage of cells in S phase (Figure 4K) and consistently a
higher proliferative potential (Figure 4C) when compared to non-stimulation oeCtrl. This finding further
supports the activation of the non-canonical TGFb pathway in the absence of SMAD4, which triggers the
activation of the oncogene RAS (Figure S6) in the downstream pathway and subsequently affects cell cycle
and proliferation.iScience 23, 101551, October 23, 2020 7
shCtrl shBMAL1 shPER2 shNR1D1 shSMAD4
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Figure 3. Dysregulation of the Core-Clock Genes (BMAL1, PER2, andNR1D1) and SMAD4 Leads to Differential Cell Proliferation and Apoptosis in
Panc1 and AsPC1 Cells
(A) Proliferation analyses of PDA cell lines for KD conditions (shBMAL1, shPER2, shNR1D1, and shSMAD4), SMAD4-OEs, and corresponding empty vectors
(shCtrl and oeCtrl, respectively).
ll
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(B) Apoptosis analysis of PDA cell lines after KDs or OEs. Data are expressed as mean G SEM, n R 6 (A and B).
(C–F) Representative images of apoptosis assays for Panc1 shCtrl and knockdown cells shBMAL1, shPER2, shNR1D1, shSMAD4 (C) or Panc1 oeCtrl and SMAD4-OE
cells (D) and AsPC1 shCtrl and knockdown cells shBMAL1, shPER2, shNR1D1 (E) or AsPC1 oeCtrl and SMAD4-OE cells (F), with fluorescently labeled caspase3/7 with




ArticleThese results demonstrate that TGFb canonical and non-canonical pathways regulate the cell cycle, prolif-
eration, and apoptosis in a SMAD4-dependent manner.The Dysregulation of the Core Clock Impacts Cell Migration in a SMAD4-Dependent Manner
Next, we aimed to examine if the activation of TGFb/SMAD4 pathway may contribute to the formation of
tumor metastasis. We used a real-time cell recording approach to measure the invasive and migration
properties of these PDA cells, analyzed known EMTmarkers, and investigated morphological cellular alter-
ations (Figure 5). TGFb1 stimulation significantly increased the migration speed in both PDA cells, partic-
ularly in SMAD4-OE cells (Figures 5B, 5C, 5E, and 5F, *p < 0.05, ***p < 0.001, n = 8). For AsPC1 oeCtrl cells,
TGFb1 stimulation did not significantly promote migration likely due to its intrinsic SMAD4 deficiency. In
contrast, Panc1 cells showed a significantly slower migration speed after SMAD4 KD (Figure 5D, **p <
0.01, n = 8) and TGFb stimulation was not able to induce the migrative potential in SMAD4 KD cells (Figures
5A and 5D), in agreement with previous data by Takano and colleagues who reported a role for SMAD4 in
the expression of EMT marker genes in pancreatic cancer (Takano et al., 2007). In addition, the resembled
phenomenon was found in invasion assays as well; TGFb1 stimulation or SMAD4 overexpression promoted
the invasiveness of PDA cells (Figures 5H and 5I), whereas SMAD4-KD without additional TGFb1 impaired
invasive ability (Figure 5G). Altogether, these data suggest that the presence of intrinsic SMAD4 and TGFb
in the tumor microenvironment is crucial for tumor invasiveness and cell motility. Cells that undergo EMT
have a greater tendency to invade and metastasize (Yang et al., 2020), thus we verified our results by quan-
tifying EMT biological makers and examining alterations in cell morphology. The cadherins aremajor adhe-
sion molecules anchoring in the cytomembrane. Epithelial cells express E-cadherin, whereas cells that
show mesenchymal features express N-cadherin and R-cadherin (Wheelock et al., 2008). Cancer cells
can enhance or reduce their metastatic potential through cadherin switching, which is one characteristic
of the EMT. Also Vimentin, a cytoskeletal molecule responsible for maintaining cell integrity and resistance
against stress (Satelli and Li, 2011), has been described as an EMT biomarker. Additionally, we also
analyzed the transcription factors SNAIL and SLUG that are sensitive to microenvironmental stimuli and
function as EMT switchers (Lamouille et al., 2014).
CD133 has been commonly used as an important biomarker to identify cancer stem cells (Glumac and LeB-
eau, 2018). We found a significant overexpression of CD133 and E-cadherin and a downregulation of Vi-
mentin and SLUG in Panc1 SMAD4-KD cells (Figure 5J, **p < 0.01, ***p < 0.001, n = 3). In contrast, E-cad-
herin expression decreased, whereas N-cadherin, Vimentin, SNAIL, and SLUG were significantly increased
in both PDA cells after SMAD4-OE (Figures 5K and 5L, *p < 0.05, **p < 0.01, ***p < 0.001, n = 3), pointing to
the initiation of the EMT process and gain of motility in SMAD4-OE cells, increasing the invasiveness po-
tential of these cells. Furthermore, the decrease in the expression level of CD133 after SMAD4-OE indi-
cated a reduction of CSCs (cancer stemness cells) along with the increased levels of SMAD4. Interestingly,
we observed morphological changes in the cells (from cuboidal shaped to spindle shaped), after the acti-
vation of the TGFb canonical pathway (Figure S7). The morphological cellular change may facilitate cells to
traverse the cellular matrix into intercellular spaces. Consistently, the upregulation of Vimentin pointed to
an alteration of the cytoskeleton in SMAD4-OE cells (Figures 5K and 5L). However, this morphological
change was not observed in the SMAD4-deficient or SMAD4-KD cells.
Altogether, these results reinforce the important role of SMAD4 and TGFb in the EMT process and PDA
cancer metastasis; on the other hand, the absence of SMAD4 enhanced tumor stemness in our PDA model
system.
We then further analyzed the possible role of the interplay between the TGFb pathway and the biological
clock in the formation of cancer metastasis. Interestingly, cell migration decreased upon PER2 KD, but
increased after NR1D1 KD in SMAD4-proficient cells (Panc1, Figures 6A and 6C, ***p < 0.001, n = 3), in
contrast to the results in SMAD4-deficient cells (AsPC1, Figures 6B and 6D, ***p < 0.001, n = 3).
The TGFb stimulation promoted the migration properties in clock genes KDs Panc1cells (Figure 6E,iScience 23, 101551, October 23, 2020 9
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Figure 4. Clock Disruption and the Activation of the TGFb/SMAD4 Pathway Affects Apoptosis and Cell Cycle in PDA Cells
(A–C) Proliferation analysis of PDA cells containing SMAD4-OE (A, C) or SMAD4-KD (B) constructs and their corresponding empty vectors (shCtrl or oeCtrl)
stimulated with additional TGFb1 (10ng/ml) or its solvent.(n = 8; mean G SEM).
(E–G) Apoptosis analysis of PDA cell lines after SMAD4-OE (E, G) or SMAD4-KD (F) and their corresponding empty vectors (shCtrl or oeCtrl) with 24-h
stimulation with TGFb1 or its solvent (n = 3, mean G SEM).
(D and H) Cell cycle measurements after clock gene KDs (shBMAL1, shPER2, shNR1D1) and its empty control (shCtrl) in Panc1 (D) and AsPC1 (H) cells.
(I–K) Cell cycle measurements of SMAD4-KD and SMAD4-OE and corresponding control conditions (shCtrl and oeCtrl) in Panc1 (I, J) and AsPC1 (K) cells after
a 24-h stimulation with TGFb1 (10 ng/mL) or its solvent. (D and H–K) Phase distributions were compared with their respective control conditions (n =3,
mean G SEM, two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).




Article*p < 0.05, **p < 0.01, ***p < 0.001, n = 3). TGFb stimulation did not alter the migration ability of AsPC1 cells
containing empty vectors (Figures 5F and 6F). On the other hand, TGFb stimulation repressed migration in
shBMAL1 and shPER2 and induced it in shNR1D1 cells (Figure 6F, *p < 0.05, **p < 0.01, ***p < 0.001, n = 3),
indicating that the interactions of the clock and the TGFb non-canonical pathway may modify migration
properties in SMAD4-deficient cells (AsPC1).
Therefore, we examined the expression level of clock genes after a 24-h TGFb stimulation compared to
Ctrl. We found that TGFb stimulation upregulated NR1D1 expression in AsPC1 (SMAD4-deficient)
NR1D1 KD cells (Figure S8D, ***p < 0.001, n = 3). Considering the decreased migration potential observed
upon NR1D1 KD (Figure 6B), the overexpression of NR1D1 resulting from TGFb stimulation (Figure S8D)
might be the cause of the increase in migration in NR1D1 KD cells (Figure 6F).
We further carried out trans-well invasion assays, which are more similar to the in vivo scenario. The results
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Figure 5. Migration and Invasion Analysis of SMAD4-KD and SMAD4-OE PDA Cells With or Without TGFb1 Stimulations and Corresponding
Expression Levels of EMT Markers
(A–C) Migration assays were performed with the IncuCyte S3 Live Cell System Analysis using a scratch wound assay. Partial representation of the scratch
wound assay for SMAD4-KD (A) or SMAD4-OE (B, C) and their control (shCtrl and oeCtrl) conditions in PDA cells with additional TGFb1 or its solvent
stimulation at 0, 24, 48 h. Images were obtained with the IncuCyte S3 Software. Yellow mask indicates the wound boundaries. Blue mask indicates the initial
scratch wound area.
(D–F) Average cell migration speed distribution in Panc1 (D, E) and AsPC1 (F) cells containing SMAD4-KD or SMAD4-OE constructs and their empty vectors
(shCtrl and oeCtrl) with additional TGFb1 or its solvent stimulation, (n R 8, mean G SEM; two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001)..
(G–I) Invasion assays were carried out using a chemotaxis cell invasion assay for the IncuCyte S3 Live Cell System Analysis. Trans-well invasion assays
for SMAD4-KD (G) or SMAD4-OE (H, I) and their control (shCtrl and oeCtrl) conditions in PDA cells were measured every 2h. Quantification was performed by
measuring the total phase area of the bottom layer of the inner chamber within 72 h. Data were normalized for the initial value (n R 6, mean G SEM).
(J–L) Expression levels of EMT and cancer stemness-related genes (E-cadherin,N-cadherin, Vimentin, SNAIL, SLUG,and CD133) in SMAD4-KD (J) or SMAD4-
OE ( K, L) conditions compared with their control conditions, shCtrl and oe-Ctrl respectively (n = 3, mean G SEM, t test, *p < 0.05, **p < 0.01, ***p < 0.001).




ArticleWe quantified the expression ofN-cadherin, E-cadherin, Vimentin, SNAIL, and SLUG. Although the expres-
sion of E-cadherin was not significantly altered in PER2 KD Panc1 cells, the expression of key MET (mesen-
chymal-epithelial transition, the reverse process of EMT) markers (N-cadherin, Vimentin, and SLUG) were
significantly reduced, which hints toward initiation of MET in these cells, compared to the control cell
line (Figures 6I and S8A, *p < 0.05, **p < 0.01, ***p < 0.001).
Although N-cadherin expression was not significantly altered (Figure 6I), the significant overexpression of
SNAIL and SLUG in Panc1 cells upon NR1D1 KD (Figure S8A) suggested that NR1D1 KD initiated the EMT
process in Panc1 cells, which is further supported by our results on migration and invasion. In AsPC1 cells,
N-cadherin expression increased significantly upon PER2 KD, whereas NR1D1 KD led to the downregula-
tion of SLUG (Figures 6J and S8B, *p < 0.05, ***p < 0.001, n = 3). Thus, PER2 KD triggered the EMT process
in AsPC1 (SMAD4 deficient) cells, as supported by our results from the migration and invasion assays. Inter-
estingly, N-cadherin was significantly increased, but SLUG was suppressed in AsPC1 shBMAL1 cells (Fig-
ures 6J and S8, ***p < 0.001). However, there was no significant increase of the migration ability of
shBMAL1 when compared with shCtrl (Figure 6B). Furthermore, CD133 was overexpressed in PER2 KD
for both PDA cell lines (Figures 6I and 6J, *p < 0.05), pointing to a role of PER2 as a potential suppressor
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Figure 6. Dysregulation of Core-Clock Genes Affects Migration of Panc1 and AsPC1
(A, B, E, and F) Migration properties of shCtrl and knockdown cells (shBMAL1, shPER2, and shNR1D1) of Panc1 and AsPC1 with stimulation of TGFb1 (10 ng/
mL) or its solvent. Migration assays were performed using a scratch wound assay for the IncuCyte S3 Live Cell System Analysis. Average cell migration speed
distribution from Panc1 and AsPC1 cells (n R 8, mean G SEM; (A and B): one-way ANOVA; (E and F): t test, *p < 0.05, **p < 0.01, ***p < 0.001).
(C and D) Partial representation of the scratch wound assay for Panc1 (C) and AsPC1 (D) knockdown (shBMAL1, shPER2 and shNR1D1) and control (shCtrl)
cells at 0, 24, and 48 h. Images were obtained with the IncuCyte S3 Software. Yellow mask indicates the wound boundaries. Blue mask indicates the initial
scratch wound area.
(G, H, K, and L) Invasion assays were carried out using a chemotaxis cell invasion assay for the IncuCyte S3 Live Cell System Analysis. Invasion assay for shCtrl
and knockdown (shBMAL1, shPER2 and shNR1D1) conditions in Panc1 (G, K) and AsPC1 (H, L) cells with or without TGFb1 stimulation (10 ng/mL).
Quantification was performed by measuring the total phase area of the bottom layer of the inner chamber within 72 h. Data were normalized to the initial
value and presented as mean G SEM, n R 6.
(I and J) mRNA levels of CD133, Vimentin, E-cadherin, and N-cadherin in PDA cells were analyzed after knockdown of core-clock genes (shBMAL1, shPER2,
shNR1D1). Data shown as comparison to the shCtrl (mean G SEM, n = 3, t test, *p < 0.05, **p < 0.01, ***p < 0.001).




ArticleIn addition, TGFb impacts the expression of clock genes in a SMAD4-dependent manner (Figures S8C and
S8D). BMAL1 and NR1D1 were upregulated in SMAD4-proficient cells (Panc1), and PER2 was upregulated
in SMAD4-deficient cells (AsPC1). These alterations on clock gene expression observed in shCtrl cells were
not present upon BMAL1 andNR1D1 KDs in Panc1 and PER2 KD in AsPC1. The expression of clock genes in
AsPC1 shBMAL1 revealed no significant difference with or without additional TGFb. These results indicated
that TGFb upregulated the expression of core-clock genes differentially via the canonical and non-canon-
ical pathway in our PDA cell model system.
The Knockdown of Core-Clock Genes and Modifications of the TGFb Canonical Pathway
Impact Treatment Response and Patient Survival
The main problem in current PDA standard therapy with gemcitabine is the rapid development of chemo-
resistance. Gemcitabine, an analog of deoxycytidine, leads to DNA fragmentation and cell death by inhib-
iting DNA chain elongation (Noble and Goa, 1997). We further investigated whether SMAD4 or clock
dysfunction impacts the response of gemcitabine in our vitro model system. Our results showed that
SMAD4-OE PDA cells were remarkably more sensitive to gemcitabine compared with oeCtrl, whereas
shSMAD4 cells were resistant to gemcitabine (Figures 7A–7C). Next, we explored the differential drug
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Figure 7. The Downregulation of Core-Clock Genes and the Alteration of SMAD4 Expression Affects Drug Response in Panc1 and AsPC1 Cells
Cytotoxicity assays were performed using either an IncuCyte Red Cytotoxicity Reagent or NucLight Rapid Red Reagent for the IncuCyte S3 Live Cell System
Analysis
(A–C) Cytotoxicity analysis for Panc1 (A, B) and AsPC1 (C) cells containing SMAD4-KD or SMAD4-OE constructs, in comparison with the corresponding
empty controls (shCtrl and oeCtrl). 0 h after cell synchronization, gemcitabine was dissolved in IncuCyte Red Cytotoxicity Reagent and added to PDA cells
(IC50: Panc1, 9.5 mM, and AsPC1, 23.9 mM). A cytotoxic index was calculated on IncuCyte S3 Live-Cell Analysis System in red phases. Data are expressed as
mean G SEM, n R 6.
(D and E) Cytotoxicity analysis for Panc1 (D) and AsPC1 (E) cells containing knockdown constructs (shBMAL1, shPER2 and shNR1D1) or its empty vector
(shCtrl). Cell nuclei were labeled with NucLight Rapid Red Reagent. At 0 h after cell synchronization, gemcitabine (IC50: Panc1, 9.5 mM, and AsPC1, 23.9 mM)
was added into the cells. 72 h after treatment, the number of viable cells per well was quantified with IncuCyte S3 Live-Cell Analysis System. Compared with
the shCtrl (mean G SEM, n = 6, one-way ANOVA, ***p < 0.001). See also Figure S9.
(F) Impact of alterations in our 10 candidate genes on progression-free survival (PFS) in a TCGA cohort of patients with pancreatic adenocarcinoma.
(G) Impact of SMAD4mutation on PFS in a TCGA cohort of patients with pancreatic adenocarcinoma when compared with patients who do not have SMAD4
mutation (log rank p < 0.05).
(H) Impact of variation in candidate gene expression on overall survival in a TCGA cohort of patients with pancreatic adenocarcinoma. Survival curves were
plotted using a Cox model that includes coxph (Surv (times, died) ~ gene + grade1 + grade2 + grade3 + age). Statistically significant results (p < 0.05) are





ArticleAsPC1(23.9mM) is much higher than that of Panc1 (9.5mM), AsPC1 shCtrl cells revealed higher viability after
72-h treatment when compared with Panc1 shCtrl. This further confirms an increased resistance to gemci-
tabine in the absence of SMAD4, in PDA cells. Unlike AsPC1, Panc1 clock gene KD cells showed significant
resistance to gemcitabine treatment compared with shCtrl cells (Figures 7D and 7E, ***p < 0.001). These
results emphasize the importance of circadian dysfunction in gemcitabine resistance in SMAD4-proficient
PDA cells. The dysregulation of the circadian clock in Panc1 cells increased the resistant to gemcitabine,
when compared with SMAD4-deficient cells (AsPC1), suggesting that SMAD4 impacts gene expression
programs associated with the circadian clock and drug response in Panc1, which are distinct from
AsPC1. These data highlight a novel role of the circadian clock in fine-tuning drug effectiveness in PDA
with an emphasis on SMAD4. Moreover, to test whether drug administration at different times had different
effects, we selected the time points 17, 20, and 23 h based on the time course RT-qPCR and biolumines-
cence data for the two cell lines, which show different expression of the core-clock genes measured
(Figure S9A). Our data show that the timing of treatment administration has different effects in cell survival
depending also on the additional perturbations generated to the cells. At particular times, the SMAD4-
proficient PDA cells are more resistant to treatment, whereas for the SMAD4-deficient AsPC1 cells this ef-
fect was not observed (Figures S9B and S9C). After downregulation of SMAD4 in Panc1 (Figure S9B), the
differential drug response to different treatment time points is significantly impaired. These results point
to a role of SMAD4 in the time-dependent effect of treatment administration.
We then analyzed the impact of alterations in the clock genes BMAL1, PER2, NR1D1, CRY1, DEC1, and
DEC2, as well as elements of the TGFb pathway, TGFb1, SMAD3, SMAD4, and SMAD7 in patient survival.
For that we quantified the mutational frequencies of these 10 genes from a cohort of patients with pancre-
atic adenocarcinoma (184 samples from the PanCancer study, Study Accession No: phs000178, https://por-
tal.gdc.cancer.gov/projects/TCGA-PAAD) (Cancer Genome Atlas Research Network, 2017) curated from
The Cancer Genome Atlas (TCGA) database. Among these candidate genes, SMAD4 showed the highest
mutation rate in the population (34%).
Patients with SMAD4mutation (mostly deletion) had a significant worse progression-free survival (PFS, p <
0.05) (Figure 7G). This suggested that SMAD4 mutation in the advanced stage of the disease facilitates
cancer progression. Interestingly if we compare the survival between the group of patients having no mu-
tations for any of the candidate genes with the patients having mutations in at least one of the candidate
genes, our results show a statistically significant influence on PFS (p < 0.05, Figure 7F). These results sug-
gest that SMAD4mutation alone had a significant impact on the PFS, which is likely to be increased with the
influence of additional mutations in our other candidate genes (Figures 7F and 7G).
To study the influence of alterations in gene expression for the set of genes described earlier in survival of
patients, we performed a cox-regression-based survival analysis based on clinical parameters that include
age, tumor grade, and gender in addition to the gene expression levels (Figure 7H). To evaluate high- and
low-risk groups based on gene expression changes, we applied OncoLnc to 177 available mRNA datasets




Articleequal cohorts (N = 87 low, N = 87 high) representing high- and low-expression groups, respectively (Fig-
ure 7H). The clock genes CRY1 and DEC1, and TGFb signaling family members SMAD3 and SMAD4,
showed significant impact on survival (Figure 7H, log rank test p < 0.05) for PDA patients suggesting a po-
tential clinical value for targeting these genes in a therapeutic context. Together with the results from our
in vitro model, the expression of the clock genes DEC1 and CRY1 also revealed a SMAD4 dependency.
These data highlight an important role for the cross-talk between the endogenous molecular clock and
the TGFb canonical pathway and its likely contribution to the progression and prognosis of PDA.DISCUSSION
A dysregulated clock in patients with cancer was shown to be associated with poorer prognosis and a
shorter lifespan. Pancreatic cancer is one of themajor causes of cancer mortality worldwide. Several studies
have identified disruptions in clock genes, which are correlated with cancer progression in pancreatic can-
cer (Jiang et al., 2016; Relles et al., 2013; Tavano et al., 2015; Wu et al., 2012). Among these genes are mem-
bers of the core-clock machinery (BMAL1 and PER2), as well as clock-regulated genes (SIRT1 and DEC1),
which either show abnormal expression or altered rhythmic pattern resulting in cancer progression and
EMT (Jiang et al., 2016; Relles et al., 2013; Tavano et al., 2015; Wu et al., 2012). However, the detailed mech-
anism of circadian clock regulation in pancreatic cancer is still unclear. TGFb is involved in oncogenic trans-
formation and cancer progression, and it plays a vital role in cancer homeostasis. As tumors grow and prog-
ress, genetic alterations often occur on TGFb canonical signaling components (including SMAD4
mutations), leading to the activation of pro-oncogenic pathways such as RAS, PI3K, and MAPK (Principe
et al., 2017). These genetic modifications eventually override the growth inhibitory effects of the TGFb ca-
nonical pathway, further contributing to tumor development. Although it is known that elements of TGFb
canonical pathway are involved in circadian regulation (Akagi et al., 2017; Chen et al., 2015; Sato et al.,
2019), the molecular mechanisms underlying this cross-talk in human cancers remain largely
uncharacterized.
In the present study, we first characterized the circadian phenotype of pancreatic cancer cells, with similar
proliferation profiles, originated from a primary tumor (Panc1) and metastasis ascites (AsPC1). The cells
derived from the primary tumor show a differential clock phenotype when compared with the cells derived
from the metastasis ascites, pointing to a differential regulation of the clock machinery in different types,
genomic background, and stages of cancer, in agreement with previous reports for other cancer types
(Fuhr et al., 2018; Relogio et al., 2014).
To explore the possible mechanisms connecting the circadian clock and tumor progression in pancreatic
cancer, we focused on the CCG SMAD4. As the core mediator of the TGFb canonical pathway, SMAD4 is
known to assist the modulation of cancer progression (reviewed in Xu et al., (2009)). We hypothesized
that SMAD4 could affect the circadian phenotype and subsequently malignant phenotypes of PDA cells.
Hence, we established a pancreatic cancer in vitro model consisting of SMAD4-positive (Panc1) and
SMAD4-negative (AsPC1) cell lines and investigated this interplay through gene knockdown and overex-
pression of core-clock elements, TGFb and SMAD4. Our data show that TGFb1, SMAD3, SMAD4, and
SMAD7 exhibit circadian oscillation at the transcript level in Panc1 cells, pointing to the circadian regula-
tion of the TGFb pathway in SMAD4-proficient PDA cells. Chen et al. reported that the transcript of TGFb1
oscillates in a circadian fashion in mouse embryonic fibroblasts, whereas the oscillation is perturbed in
Clock-deficient mice (Chen et al., 2015). Furthermore, the authors showed that binding of the Bmal1-Clock
heterodimer to mTGFb1 exhibits a circadian rhythmicity in mouse renal cells (Chen et al., 2015). Another
study showed enriched Bmal1 binding on promoter regions of TGFb1 and Smad3, which occurred at the
similar time as Bmal1 E-box binding to Nr1d1 (at CT8) in mouse brown adipocytes (Nam et al., 2015). These
results indicate that Bmal1 activates the expression of components of the TGFb canonical pathway (via
TGFb1 and Smad3) in parallel with the activation of Nr1d1. However, whether mRNA dynamics of TGFb
signaling elements are under the circadian modulation in human cancers is still largely uncharacterized.
Interestingly, our results show that the circadian oscillation (period of circa 24 h) of elements of the
TGFb pathway is only detectable in SMAD4-positive cells and not in SMAD4-deficient cells. In the absence
of extrinsic TGFb, transcription of SMAD7 can be induced by the intrinsic TGFb following a circadian
pattern. TGFb1 transcript also shows a similar period with a different phase than SMAD7. This further sug-
gests that autocrine TGFbmay activate the transcription of SMAD7 in a circadian fashion. We also detected




ArticleTGFb canonical elements (SMAD3 and TGFB1). This supported our hypothesis that SMAD4 may serve as a
mediator element bridging the clock and the TGFb signaling pathway.
It has been previously shown that the core-clock genes Bmal1 andNr1d1 are involved in the TGFb canonical
pathway in mouse brown adipose (Nam et al., 2015). In agreement, we show that clock perturbation via
small hairpin RNA knockdown of core-clock elements (BMAL1 and NR1D1) resulted in abolished oscilla-
tions of TGFb1, SMAD3, SMAD4, and SMAD7, confirming the existence of bidirectional connection
between core-clock elements and the TGFb canonical pathway in human PDA cells. In addition, the tran-
scription factors, DEC1 and DEC2, inhibit PER via protein-protein interactions with BMAL1 and/or compe-
tition for E-box elements (Honma et al., 2002). Of note, DEC1/2 is a downstream element of TGFb canonical
pathway as well (Adorno et al., 2009; Kon et al., 2008; Prunier et al., 2019; Zawel et al., 2002). To identify the
specific bridging elements between the core-clock and the TGFb signaling, we further analyzed the expres-
sion of the clock genes DEC1 and DEC2 (Figures 2D, 2G, and 2J). We observed a negative correlation be-
tween SMAD4 and DEC1/2 expression through SMAD4 downregulation and overexpression assays, which
reinforced the mediating role of DEC1/2 via TGFb pathway in regulating the circadian clock.
We further investigated whether TGFb activation and SMAD4 expression could affect the oscillatory
phenotype of BMAL1 and PER2 promoter activity in both SMAD4-positive and SMAD4-deficient pancreatic
cancer cell lines using live bioluminescence recordings. Surprisingly, TGFb stimulation alone did not cause
major changes in the period of oscillations for both cell lines. However, the period was significantly shorter
when we combined TGFb stimulation with SMAD4 overexpression in both cell lines, indicating that the
TGFb-clock interplay might be SMAD4 dependent.
Downregulation of core-clock genes resulted in an overall higher proliferative and apoptotic activity in
SMAD4-positive cells. Of note, SMAD4 downregulation only affected cell proliferation and not apoptosis
in these cells. We speculate that reduced expression of SMAD4 might activate the non-SMAD TGFb
signaling pathway, including the MAPK/ERK, resulting in higher cell proliferation and growth (reviewed
in Zhang, 2017). We confirmed the activation of the Ras-mediated TGFb non-canonical pathway by
measuring the expression of RAS and p-ERK, and particularly after stimulation with TGFb, further pointing
to the activation of the RAS/ERK pathway.
In SMAD4-deficient cells, the apoptotic rate was also increased upon knockdown of clock genes. However,
cell proliferation was only notably increased upon PER2 downregulation in AsPC1. Our cell cycle analysis
also confirmed this finding showing higher percentage of shPER2 cells in the S phase. The overall differen-
tial proliferative properties and cell cycle distributions upon the KD of clock genes in both PDA cells
suggest that cell fate determination via the clock is altered in SMAD4 mutant (AsPC1) cells. SMAD4
overexpression, on the other hand, resulted in remarkably higher cellular apoptosis in both cell lines.
This confirms the apoptotic role of the canonical TGFb signaling pathway mediated by SMAD4, as
described in previous studies, and hints to the central role of SMAD4 in regulating the canonical TGFb
signaling pathway (Du et al., 2018; Pang et al., 2011). This effect is more evident in our SMAD4-deficient
cells, with a notable increase in apoptosis upon SMAD4 overexpression with additional TGFb1 stimulation.
Previous reports indicate a prominent role for the TGFb signaling pathway in regulating cell cycle progres-
sion (Buenemann et al., 2001; Mukherjee et al., 2010; Voss et al., 1999). Indeed, we showed in our PDA
model that cell-cycle arrest was triggered when cells were stimulated with TGFb and SMAD4 was overex-
pressed. We observed an opposite effect after SMAD4 downregulation resulting in more S-phase cells and
proliferation. Furthermore, TGFb stimulation alone inhibited G1/S cell cycle propagation only in SMAD4-
positive cells. These results highlight the determinant role of SMAD4 in regulating cell cycle proliferation
and apoptosis via downstream genes of TGFb canonical and non-canonical signaling pathway (e.g., P21, c-
MYC, and RAS) (Alexandrow andMoses, 1995; Mukherjee et al., 2010; Principe et al., 2017; Voss et al., 1999),
further pointing to a differential regulation of TGFb pathway in different stages of pancreatic cancer, as re-
ported in the present or former studies in a SMAD4-dependent manner.
Regulating EMT and cell invasion is one of the key functions of TGFb signaling pathway in cancer cells (Lee
et al., 2013; Xu et al., 2009). Cells undergoing EMT lose expression of E-cadherin and other components
needed for epithelial cell junction stability and are able to produce a mesenchymal cell cytoskeleton




Articlethe activation of E-cadherin and suppression of N-cadherin (Yao et al., 2011). Hence, we analyzed migra-
tion/invasion properties upon SMAD4 expression and TGFb stimulation in both cell models. TGFb stimu-
lation alone was sufficient to enhance cell migration in SMAD4-positive cells, whereas in SMAD4-deficient
cells, both SMAD4 overexpression and TGFb stimulation resulted in the highest migratory and invasion ac-
tivities, suggesting that SMAD4 expression is necessary for enhancing cancer metastasis. We confirmed
this finding through SMAD4 downregulation and showed that cell migration was not affected upon
TGFb stimulation. After measuring the expression of EMT marker genes (e.g., E-Cad, N-Cad, SNAIL,
SLUG) in pancreatic cancer (Takano et al., 2007), we found that SMAD4 overexpression reduced the expres-
sion of epithelial marker genes (E-Cad) and enhanced the expression of genes involved in mesenchymal
transition (N-Cad, Vim, SNAIL, and SLUG) in both cell lines, indicating that SMAD4 mediates invasion by
regulating the expression of key marker genes involved in EMT. We observed the opposite effect in
EMT gene expression after SMAD4 knockdown, which reinforces the role of SMAD4 in cancer invasion.
In addition, we sought to explore another cancer hallmark, tumor stemness via the analysis of CD133
(Tabu et al., 2010). In our model system, we observed a downregulation of CD133 in PDA cells with
SMAD4 overexpression. More interestingly, increased CD133 expression after SMAD4 KD implied the
acquisition of cancer stem-like hallmark in our study, in agreement with previous studies (Chen et al., 2014).
Cancer metastasis is the cumulative result of multiple changes in tumor cells and their microenvironment.
Cell migration was differentially regulated in SMAD4-positive and SMAD4-deficient cells upon PER2 and
NR1D1 downregulation (Figure 6). In SMAD4-positive cells, cell migration was decreased upon PER2
knockdown and increased after NR1D1 downregulation, whereas we observed an opposite effect in the
cell line deficient for SMAD4. Interestingly, TGFb activation also implied an overall opposite effect in the
core-clock knockdown cells from SMAD4-positive and SMAD4-negative PDA: promoting migration in
Panc1 cells and inhibiting it in AsPC1 cells. These results show that cancer cell properties seem to be
SMAD4-dependent upon clock dysregulation, highlighting the reciprocal role of the circadian clock and
SMAD4 in pancreatic cancer. Notably, the downregulation of PER2 results in the increased expression of
CD133 in both PDA cells, hinting at the crucial role of PER2 in cancer stemness independent of SMAD4 (Ka-
tamune et al., 2019). Hence, based on our results on proliferation, apoptosis, cell cycle, and cellular met-
astatic proprieties, we speculated that TGFb might alter the circadian clock differently via the canonical
(in Panc1) and non-canonical (in AsPC1) pathways.
Finally, we tested whether treatment response in pancreatic cancer is clock and/or SMAD4 dependent. Re-
sults from previous clinical trials concluded that the loss of SMAD4 is a negative prognostic indicator, which
is strongly associated with poor chemosensitivity (Shin et al., 2017; Singh et al., 2012; Yamada et al., 2015).
Extrinsic DNA damage due to gemcitabine administration imposes threats to cellular homeostasis
involving the regulation of both the TGFb signaling pathway (Li et al., 2019; Liu et al., 2019) and clock com-
ponents (Jiang et al., 2018; Ka et al., 2017; Mazzoccoli et al., 2016; Sulli et al., 2018). To elucidate the mo-
lecular mechanisms that drive chemoresistance in this PDA model, we hypothesized that during the expo-
sure to gemcitabine, clock genes and TGFb canonical components participate in the regulation of DNA
repair, as well as in the maintenance of genomic stability.
A previous study showed that patients with PDA with SMAD4 loss have poorer PFS in the gemcitabine-
based treatment subgroup (Ormanns et al., 2017). Consistently, we observed that SMAD4-deficient cells
are resistant to the chemotherapy with gemcitabine. Although the intrinsic mechanism has not been fully
understood yet, based on our apoptosis and cell cycle data, we assume that it relates to the effect in the cell
cycle due to the anti-apoptotic role of SMAD4.
Clock perturbation via the knockdownof core-clock genes aggravates chemoresistance, notably only in SMAD4-
proficient pancreatic cancer cells. Associatedwith the fact that genetic alterations (mostly inactivation) of SMAD4
often occur in the advanced stage of pancreatic cancers, we concluded that the molecular clock functions as a
repressor of chemoresistance of gemcitabine while SMAD4 is not mutated (e.g., cancers in the early stage).
Hence, loss of Smad4 function along with TGFb stimulation (as observed for AsPC1, SMAD4-deficient cells) ac-
tivates the non-canonical pathway (RAS) and increases CSCs (CD133 upregulation), further contributing to the
acquisition of malignant properties and drug resistance. These findings highlight the important role of
SMAD4 in affecting gene expression programs associated with the circadian clock and drug response in
SMAD4-proficient cells, which are distinct from those in SMAD4-deficient cells. Furthermore, our results empha-




Articledata indicate that drug response and cell fate determination in pancreatic cancer cells with WT or mutated
SMAD4, upon the dysregulation of the circadian clock, resulted in a significant differential change in cell survival
rate and invasiveness, highlighting the importance of the associations between the TGFb canonical pathway,
biological clock, and drug timing affecting chemosensitivity in a cancer context.
The information that we obtained from our in vitromodel system aids to the understanding of the impact of
the clock in the SMAD4 network and consequently in cell fate decisions. In addition, and to better show the
potential of our results beyond the in vitro experiments presented, we performed a computational analysis
with publicly available datasets for patients with pancreatic cancer. In our PDA model system, the overex-
pression of SMAD4 resulted in upregulation of CRY1 and downregulation of DEC1; the downregulation of
SMAD4 led to suppression ofCRY1 and overexpression ofDEC1. These results agree with our survival anal-
ysis for a cohort of patients with PDA that indicated a better prognosis (PFS, p < 0.05) for the groups of
patients with high expression ofCRY1, low expression ofDEC1, and high expression of SMAD4. In addition,
the genomic alteration of SMAD4 (mostly deletion) alone led to a worse PFS (p = 0.0265), which is aggra-
vated when combined with alterations of other genes bridging the clock and the TGFb canonical pathway
(p = 0.0147). This points to a relevant role of the molecular clock, together with the TGFb pathway, in
contributing to the progression and prognosis of PDA. Altogether, our data show that the circadian clock
regulates the TGFb/SMAD4 pathway in PDA cells with likely consequences on cancer progression (invasion
and EMT) and patient survival and suggest a profound role for SMAD4 as an intermediate component link-
ing the clock machinery to the TGFb pathway. This information may be relevant for patients with pancreatic
cancer undergoing chemotherapy to increase the effectiveness of the therapy based on SMAD4 mutation
and the circadian clock.
Limitations of the Study
We consider the lack of in vivo data as a limitation of our study, with the caveat that mice (as nocturnal an-
imals) have a different clock compared with humans (as diurnal animals) and hence results from an in vivo
mousemodel regarding alteration of the circadian clock may not be directly relevant or properly translated
to human disease models. This is particularly relevant when comparing drug timing, drug toxicity, and drug
efficacy between nocturnal and diurnal models (reviewed in Dallmann et al., 2016). In addition, we have pre-
viously shown that in circadian studies, the host-cancer interaction in in vivo models (using xenografts) has
an impact on the circadian phenotype of the xenograft, which adds complexity to the interpretation of the
results with regards to the circadian machinery (Basti et al., 2020).
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Figure S1. Western blot analysis of SMAD4 protein expression for KDs and OE cells. 
Related to Figure 1. (A) Western blot analysis of SMAD4 (65kDa) for wild type PDA cells and 
Panc1 KD cells (shCtrl, shBMAL1, shPER2, shNR1D1 and shSMAD4). Depicted is one 
representative replicate, GAPDH is provided as loading control. (B - C) KD efficiency 
for shBMAL1, shPER2, shNR1D1 and shSMAD4. Gene expression analysis of corresponding 
KD genes in Panc1 (B) and AsPC1 (C) cells. Relative gene expression is shown compared to 
the corresponding shCtrl (pLKO.1) (mean ± SEM, n = 3, t-test, *p < 0.05, **p < 0.01, ***p < 
0.001).  KD efficiency in Panc1 shBMAL1: 70.8% (0.29 ± 0.01), shPER2: 81.7% (0.18 ± 0.02), 
shNR1D1: 86.1% (0.13 ± 0.02) and shSMAD4: 88.5% (0.12 ± 0.02). KD efficiency in AsPC1 
shBMAL1: 76.2% (0.24 ± 0.03), shPER2: 88.7% (0.11 ± 0.02) and shNR1D1: 74.2% (0.26 ± 
0.03). (D) Proliferation assays for pancreatic cell lines (Panc1 and AsPC1) were performed 
using NucLight Rapid Red Reagent for the IncuCyte S3 Live Cell System Analysis (mean ± 






Figure S2. The promoter activity of BMAL1 and PER2 after clock genes KD. Related to 
Figure 2. Bioluminescence recordings for the promoter activity of BMAL1 and PER2 for shCtrl 
(pLKO.1) and KDs (shBMAL1, shPER2 and shNR1D1) in Panc1 (A - B) and AsPC1 (C - D). 






Figure S3. Panc1 (SMAD4 proficient) cells show circadian oscillations in expression for 
elements of the TGFβ pathway. Related to Figure 2. (A - E) 33h time-course gene expression 
analysis for TGFβ1, SMAD4, SMAD3 and SMAD7 in Panc1 and AsPC1 wild type cells (n = 3, 
mean ± SEM, a cosine curve was fitted to all data sets, Table. 3). (F - H) Comparisons of gene 






Figure S4. The real-time bioluminescence recording of a BMAL1 and PER2 promoter 





Figure S5. Clock disruption stimulated with TGFβ impacts on cell cycle in PDA cells. 
Related to Figures 3 and 4. (A) SMAD4 overexpressing efficiency after γ-retroviruses 
transduction. Gene expression analysis of SMAD4 in Panc1 and AsPC1 cells. Relative gene 
expression value is shown compared to the corresponding empty vector oeCtrl (Flag-puro). (B) 
Shown is one representative replicate for the Western blot analysis of SMAD4 (65kDa) for PDA 
cells containing overexpression construct and respective control (SMAD4-OE and oeCtrl). 
GAPDH was d as loading control. (mean ± SEM, n = 3). (C-D) Cell cycle measurements after 
KDs of BMAL1, PER2 and NR1D1 with or without a 24h-TGFβ1 stimulation. Cell cycle phase 
distributions were compared with their respective control conditions (n = 3, mean ± SEM, two-




Figure S6. Loss of SMAD4 and TGFβ stimulation promote the overexpression of p-ERK 
and RAS. Related to Figures 3 and 4. (A) Shown is one representative replicate for the Western 
blot analysis of RAS (21kDa) and phosphorylated-ERK (p-ERK, 44.42kDa) for Panc1 cells 
containing shSMAD4 construct and respective control (SMAD4-KD and shCtrl) with or without 
a 24h-TGFβ-stimulation. GAPDH (36kDa) was used as loading control. (B-C) Relative protein 
expression level of RAS, p-ERK for each condition as compared to shCtrl (one-way ANOVA, 




Figure S7. Morphology changes after activation and inactivation of the canonical TGFβ 
pathway. Related to Figure 5. SMAD4-KD and -OE cells were stimulated with 10ng/ml TGFβ1 
or the corresponding solvent. Changes in cell morphology were observed 24h after stimulation 






Figure S8. TGFβ stimulation impacts the clock gene expression differentially in SMAD4-
proficient and -deficient PDA cells. Related to Figure 6. (A - B) mRNA levels of EMT markers 
(SNAIL and SLUG) in PDA cells were altered after knockdown of core-clock genes (shBMAL1, 
shPER2 and shNR1D1). Depicted are RT-qPCR results for KD PDA cells compared to the 
shCtrl (mean ± SEM, n = 3, t-test, *p < 0.05, **p < 0.01, ***p < 0.001). (C - D) The comparison 
of clock genes (BMAL1, PER2, NR1D1 and CRY1) expression with stimulation of TGFβ1 
(10ng/ml) or its solvent. Data shown as comparison to the non-TGFβ1 stimulation (mean ± SEM, 






Figure S9. Cytotoxicity assays were performed using NucLight Rapid Red Reagent for 
the IncuCyte S3 Live Cell System Analysis. Related to Figure 7. (A) At 17h, 20h, 23h after 
cell synchronization respectively, gemcitabine was added to the cell culture medium. (B - C) 
72h after treatment, the number of living cells per well was quantified using the IncuCyte S3 
Live-Cell Analysis System. Depicted are the comparisons to the 17h time point. (means ± SEM, 
n = 6, two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001). 
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Table S1. Primer sequences. 
Primer sequence 
Gene Forward Reverse 
SMAD3 F:5'-CCCCAGAGCAATATTCCAGA-3' R:5’-GGCTCGCAGTAGGTAACTGG-3' 
SMAD4 F:5'-TGTGCCTGGTTTGATGGTAA-3' R:5’-GCCATTTTCCCAATCTGCTA-3' 
SMAD7 F:5’-TACCGTGCAGATCAGCTTTG-3' R:5’-AGTTTGAAGTGTGGCCTGCT-3' 
DEC1 F:5′-GTCTGTGAGTCACTCTTCAG-3 R:5′-GAGTCTAGTTCTGTTTGAAGG-3′ 
DEC2 F:5′-CACCTTTGACGTCTTTGGAG-3′ R:5′-GAGAGTGGGAATAGATGCAC-3′ 
E-cadherin F:5'-ATTGCAAATTCCTGCCATTC-3' R:5'-CTCTTCTCCGCCTCCTTCTT-3' 
N-cadherin F:5'-CTCCTATGAGTGGAACAGGAACG-3′ R:5'-TTGGATCAATGTCATAATCAAGTGCTGTA-3' 
Vimentin F:5'-GGGAGAAATTGCAGGAGGAG-3' R:5'-ATTCCACTTTGCGTTCAAGG-3' 
CD133 F:5'-CCCCAGGAAATTTGAGGAAC-3' R:5'-TCCAACAATCCATTCCCTGT-3' 
SNAIL F:  5′-GAGGCGGTGGCAGACTAG-3′ R: 5′-GACACATCGGTCAGACCAG-3′  






















The PDA cell lines Panc1 and AsPC1 were used as an in vitro model system for our study. 
Panc1 (ATCC: CRL-1469) was derived from the primary tumor of a male patient with a doubling 
time of 52h (Lieber et al., 1975). AsPC1 (ATCC: CRL-1682) was established from ascites of a 
female patient with similar doubling time as Panc1 (Watanabe et al., 2012). Both cell lines were 
maintained in RPMI 1640 (Gibco, CA, USA) supplemented with 1% penicillin-streptomycin 
(Gibco) and 10% fetal bovine serum (Gibco). For lumicycle measurements and IncuCyte S3 
analysis, RPMI 1640 (Gibco) was supplemented with 10μM HEPEs (Gibco) to avoid pH 
variation. All cells were incubated at 37°C in a humidified atmosphere with 5% CO2. 
 
Lentivirus production of Bmal1: Luc, Per2: Luc reporters and shRNA-mediated 
knockdown 
Lentiviral elements containing a BMAL1-promoter-driven luciferase (BLH) or a PER2-promoter-
driven-Luciferase (PLB) were generated as previously described (Brown et al., 2005). For the 
knockdown of BMAL1, PER2, NR1D1 and SMAD4, a TRC lentiviral shRNA glycerol set 
(Dharmacon Inc., Lafayette, CO, USA) specific for each gene was used consisting of 5 - 6 
individual shRNAs. The construct with best knockdown efficiency was determined by RT-qPCR 
or Western-blot analysis and used for further experiments. 
For lentiviral production, HEK293T (ATCC: CRL-11268) cells were seeded in a 75 cm2 cell 
culture flask and co-transfected with 4.2 µg packaging plasmid psPAX, 2.5 µg envelope plasmid 
pMD2G and 5.8 µg expression plasmid (Bmal1:luc-hygromycin, PER2:luc-Blasticidin, pLKO.1 
empty vector or specific knockdown plasmids) using the CalPhos mammalian transfection kit 
(Clontech Fremont, CA, USA) according to the manufacturer's instruction. Virus particles were 
harvested and centrifuged at 4000xg for 15 min to remove cell debris. The supernatant was 
filtered (0.45 μm filter, Sarstedt, Nümbrecht, DE) and used for lentiviral transduction.  
 
Retrovirus production for SMAD4 overexpression 
pBabe-puro-Smad4-Flag was a gift from Sam Thiagalingam (Addgene plasmid # 37041; 
http://n2t.net/addgene:37041; RRID: Addgene_37041). To generate retrovirus, HEK293T 
(human, kidney, ATCC: CRL-11268) cells were seeded in 75 cm2 culture flasks and co-
transfected by 6µg pBabe-puro empty vector or pBabe-Smad4-Flag along with 0.3 µg PMD2.G 
envelope and 2.7µg pUMVC packaging plasmids using FuGENE HD Transfection Reagent 
(Promega, WI, USA) according to manufacturer's introduction. The supernatant was replaced 
after 12 h, subsequently, retroviral particles were collected at 24h and 36h after incubation. The 
retroviral particles were centrifuged at 4100xg for 15 min to remove cell debris filtered (45 µm 





Lentivirus and retrovirus transduction 
Cells were transduced with 1.5 ml virus filtrate including 8 µg/µl protamine sulphate (Sigma, 
MO, USA) and 4 µg/µl polybrene (Sigma) in 6-well plates. To enhance transduction efficiency, 
plates were centrifuged at 800xg for 90 minutes at 35°C. Subsequently, the supernatant was 
replaced after 6 - 8 hours. Stably-transduced cells were selected using the corresponding 
antibiotics (BMAL1: Luc hygromycin, PER2: Luc blasticidin; shBMAL1, shPER2, shNR1D1, 
shSMAD4 and pLKO.1 empty vector puromycin; pBabe-puro empty vector and pBabe-Smad4-
Flag puromycin). Untraduced cells were used as control. pLKO.1 empty vector and pBabe-puro 
empty vector are referred as shCtrl and oeCtrl respectively. 
 
Cell synchronisation 
For all experiments, cells were synchronized by medium change. For the cytotoxicity analysis, 
time point 0 h is defined as the time point of medium change. Untreated control cells were 




For live-cell bioluminescence measurements, cells were seeded onto 35mm dishes (Thermo 
scientific MA, USA) and maintained in phenol red-free RPMI1640 (Gibco) containing 10% FBS, 
1% penicillin-streptomycin, 10µM HEPES supplemented with 250 μM D-Luciferin (PJK, 
Kleinblittersdorf, DE). Prior to the measurement, cells were synchronized by medium change 
and washed with 1xPBS twice to avoid the influence of phenol red. Subsequently, the live-cell 
bioluminescence was recorded by a LumiCycle instrument (Actimetrics, Wilmette, IL, USA) for 
five consecutive days. For live-cell bioluminescence measurements of SMAD4 knockdown or 
overexpression with TGFβ1 stimulation, cells were treated and maintained with 10ng/ml TGFβ1 
(Stem Cell Technologies, Vancouver, CA) for five consecutive days. The concentration of 
TGFβ1 was retrieved from a previous publication (Ellenrieder et al., 2001). Chronostar software 
was used for data analysis (Sporl et al., 2011). The data of the first 12 hours was automatically 
excluded to avoid the influence of intrinsic noise of the device. Bioluminescence measurements 
were performed at least three times, as indicated. 
 
RNA extraction and gene expression analysis by RT-qPCR 
Total RNA was isolated with the plus RNeasy Mini kit (Qiagen, Venlo, NL) following the 
manufacturer’s instructions. For a single time-point RT-qPCR, cell medium was replaced by 
fresh medium 3 hours before RNA extraction. Subsequently, the medium was discarded and 
cell pellets were washed twice with 1xPBS. To digest genomic DNA, homogenized cell lysates 
were passed through gDNA eliminator spin column with a 30s centrifugation at 17000xg. RNA 
was eluted in 20-30 μl Rnase-free water. The final RNA concentration was measured using a 
Nanodrop 1000 (Thermo Fisher Scientific) and stored at -80 °C for further usage. For RT-qPCR 
analysis, the extracted RNA was reverse transcribed into cDNA by using random hexamers 
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(Eurofins MWG Operon) and Reverse Transcriptase (Life technologies). RT-qPCR was 
performed using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories, 
Hercules, CA, USA) in 96-well plates. For the detection of human gene expression, primers 
were either custom designed (Table. S1) or a human Quantitect Primer assay (Qiagen) was 
used. Gene expression levels were normalised by Gapdh mRNA. The qPCR was performed in 
a CFX Connect Real-Time PCR Detection System (Biorad). Relative gene expression was 
calculated using the 2-ΔΔCt method (Livak and Schmittgen, 2001). Mean and SEM were 
calculated including biological and technical replicates.  
 
Proliferation assays 
For the proliferation assay, 5000 cells/ well of each condition were seeded in a 96-well plate 
(Sarstedt). Cells were allowed to adhere. Subsequently, the medium was replaced with fresh 
medium containing TGFβ1 or its solvent. Plates were measured in the IncuCyte® S3 Live Cell 
System Analysis (Sartorius, Göttingen, Germany). Four images per well were recorded every 
2 hours. The analysis was performed using the IncuCyte S3 Software (Sartorius).  
For TGFβ1 stimulation, stimulated and control cells were treated with and maintained in 
10ng/ml TGFβ1 (Stem Cell Technologies, Vancouver, CA) or its solvent (0.1% BSA, Sigma) for 
five consecutive days. 
 
Apoptosis assays 
Cells were seeded in a 96-well plate (Sarstedt) at a concentration of 5000 cells/ 100 µL RPMI 
medium and incubated overnight at 37 °C with 5% CO2. After incubation, cell media were 
replaced with fresh medium containing caspase 3/7 reagent (Sartorius, 1:2000) and TGFβ1 or 
its solvent. Cell apoptosis was measured using the IncuCyte® S3 Live Cell System Analysis 
(Sartorius). Cells were scanned every 2 hours with a 20x objective and by using the phase and 
green image channels.  
 
Migration assays 
60000 cells/ well of each condition were seeded in a 96-well Essen Image Lock TM microplate 
(Essen BioScience, Michigan, USA) and incubated overnight at 37 °C, 5% CO2. In the next day, 
the WoundMakerTM (Essen BioScience) was used to create precise and reproducible wounds. 
Subsequently, the medium was replaced with a fresh medium containing TGFβ1 (10 ng/mL) or 
its solvent and the plate was placed in the IncuCyte® S3 Live Cell System Analysis (Essen 
BioScience). Image acquisition was performed by setting the “scan type” to Scratch Wound and 
Wide Mode, using the 10x objective. The plate was scanned every 2 hours. The analysis was 
performed in the IncuCyte S3 Software (Sartorius), the wound width for each well were exported 
and the migration speed were calculated using either the time of wound closed or the cut-off of 
48 hours, which is shorter than the doubling-times of Panc1 and AsPC1 (48 - 52h). Biological 





5000 cells/ well of each condition were mixed with 20µl 5mg/ml Basement Membrane Matrix 
(Trevigen Gaithersburg, MD, USA) seeded in the inner chamber of a 96-well Incucyte 
Chemotaxis cell invasion clear view plates (Sartorius). Subsequently, the plate was centrifuged 
at 50x G to avoid the formation of bubbles. Basement membrane matrix was allowed to 
polymerize at 37°C for 45 minutes to form a reconstituted basement membrane. Cell invasion 
was measured using the IncuCyte® S3 Live Cell System Analysis. Cells were scanned every 
2 h with a 20x objective and phase image channels. Biological triplicates and 8 technical 
replicates were carried out for each experiment. 
 
Cytotoxicity assays 
5000 cells/well were seeded in a 96-well plate (Sarstedt) containing 100 µL RPMI medium and 
incubated overnight at 37 °C with 5% CO2. After incubation, the supernatant was replaced with 
fresh medium containing IncuCyte® Cytotox Reagents (Sartorius, (Red)) and appropriate 
concentrations of gemcitabine (Panc1, 9.5µM; AsPC1, 23.9µM (Awasthi et al., 2013)). For the 
time-dependent treatment assay, cells were synchronized by a medium change. At specific time 
points after synchronization (17h, 20h and 23h). Gemcitabine in a solution containing 
IncuCyte® Cytotox Reagents (Red) was added into each well with a micro-pipette. Cell 
cytotoxicity was measured using the IncuCyte® S3 Live Cell System Analysis (Sartorius). Cells 
were scanned every 2 hours with a 20x objective and using the phase and red image channels. 
Biological triplicates and 8 technical replicates were carried out for each experiment. 
 
Cytotoxicity assays with live-cell nuclear labelling 
Cells were labelled with IncuCyte® NucLight Rapid Red Reagent (Sartorius) 30 min before 
measurements. Cell survival after treatment was quantified using the IncuCyte® S3 Live Cell 
System Analysis (Sartorius). The plates were scanned every 2 hours with a 20x objective and 
using the phase and red image channels. 
 
Treatment with Gemcitabine 
Treatment concentrations for each PDA cell line were determined based on the experimentally 
determined IC50 value in a previous study (Awasthi et al., 2013). 
 
Western blot 
Cells were synchronized by medium change, gently detached from the dish at 3h after 
synchronization, sedimented by low-speed centrifugation and resuspended in lysis buffer. 
Aliquots containing 20 mg of proteins from each cell lysate were subjected to SDS 
polyacrylamide gel electrophoresis and transferred to a Nitrocellulose Membranes (GE 
Healthcare Amersham™) using Trans-Blot Turbo Transfer System. Membranes were probed 
with the following primary antibodies: SMAD4 (1:5000; ab40759, Abcam, Cambridge, UK); 
GAPDH (1:20000; ab9485, Abcam); RAS (1:5000; ab52939, Abcam); p-ERK (1:2000, Cell 
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Signaling Technology, Frankfurt am Main, Germany). After incubation with corresponding 
secondary antibody (1:2000; ab205718, Abcam), signals were detected using the Amersham 
ECL Select Western Blotting Detection Reagent (GE Health care, Chicago, US), acquired by 
Image Quant LAS 4000 series (GE Health care). Data was analysed by image J v1.8 
(developed by National Institutes of Health).  
 
Cell cycle analysis 
1x106 cells under the logarithmic growth phase were collected, washed with 1xPBS (Gibco) and 
fixed with ice cold 80% ethanol. Cells were maintained in medium containing 10ng/ml TGFβ1 
stimulation (or the solvent) for 24 hours before the measurement. Subsequently, samples were 
washed with PBS and incubated in a 200ul of 1xPBS solution containing 0.5% Tween20 
(Sigma), 1% BSA (Sigma), 2 N HCl/Triton x-100 (Sigma) and 10 mg/mL of Rnase (AppliChem, 
Cat. No. A2760) for 30 minutes at room temperature. For PI staining, supernatant was removed, 
the fixed cell pellets were resuspended and stained in 500 µL of 1xPBS containing 50 µM PI 
(Sigma) for 30 minutes at 37°C. Subsequently, supernatant containing PI solution was removed 
and the stained cells were resuspended in cold 500 µL 1xPBS and read in FACS Cabilur 
(Becton Dickinson, NJ, USA). Cell cycle analysis was conducted by fitting a univariate cell cycle 
model using the Watson pragmatic algorithm as implemented in FlowJo v10.2 (FlowJo LLC).  
 
Statistical Analysis 
Experiments were carried out with at least three biological replicates per condition. Data are 
provided as mean ± SEM. p-value < 0.05 was considered as statistically significant. The 
significance of differences between groups (*p < 0.05; **p < 0.01; ***p < 0.001) was analysed 
by one-way or two-way ANOVA followed by Tukey`s multiple comparisons test and the unpaired 
two-tailed t-test or multiple t-tests using the Prism software (version 6.0; GraphPad Prism).  
 
Cosinor Analysis 
To detect significant (p < 0.05) circadian rhythmic expression, the cosinor analysis was 
performed. The p-value was calculated using a QUICK CALCS (GraphPad, 
https://www.graphpad.com/quickcalcs/pValue1/). The oscillating transcripts were estimated by 
GrapdPad Prism. 6 software and fitting a non-linear equation as following:  
𝑌(𝑡) = 𝐵 + 𝐴 ∙  (cos
2 𝜋 ∙ 𝑡
𝑃
+ 𝜑) + 𝑆 ∙ 𝑡 





Analysis of pancreatic adenocarcinoma data from a cohort of patients retrieved from the 
TCGA data base 
Clinical information for pancreatic adenocarcinoma with overall patient survival was retrieved 
from The Cancer Genome Atlas (TCGA) (https://portal.gdc.cancer.gov). Mutational frequencies 
in the TCGA PDA patient population (184 pancreatic adenocarcinoma samples from PanCancer 
Atlas) were plotted using cBio Cancer Genomics Portal (http://cbioportal.org) (Cerami et al., 
2012; Gao et al., 2013). OncoPrint functionality was used for graphical representation of 
mutation frequency for 10 candidate genes retrieved from our results. Survival curves were 
plotted using a Cox model that includes coxph (Surv (times, died) ~ gene + grade1 + grade2 + 
grade3 + age) via OncoLnc (http://www.oncolnc.org), each tumour grade is represented as a 
separate term as 1 or 0 (Anaya, 2016). The survival data includes clinical data for patients with 
complete clinical information needed for the analysis and based on a follow up or days until 
death greater than zero. Previous studies revealed contribution of additional clinical parameters 
to the benefit provided by chronotherapy (i.e., age). Therefore, in our cox survival analysis we 
included patient age as an additional clinical parameter. The PDA cohort was divided into two 
equal groups (N1=87, N2=87 patients). based on the mean expression value of the candidate 
gene, the change in gene expression levels were categorized as high or low for equal number 





Anaya, J. (2016). OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs 
(PeerJ Preprints). 
Awasthi, N., Zhang, C., Schwarz, A.M., Hinz, S., Wang, C., Williams, N.S., Schwarz, M.A., and 
Schwarz, R.E. (2013). Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-
based docetaxel in experimental pancreatic cancer. Carcinogenesis 34, 2361-2369. 
Brown, S.A., Fleury-Olela, F., Nagoshi, E., Hauser, C., Juge, C., Meier, C.A., Chicheportiche, 
R., Dayer, J.M., Albrecht, U., and Schibler, U. (2005). The period length of fibroblast circadian 
gene expression varies widely among human individuals. PLoS Biol 3, e338. 
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, 
C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform 
for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-404. 
Ellenrieder, V., Hendler, S.F., Boeck, W., Seufferlein, T., Menke, A., Ruhland, C., Adler, G., and 
Gress, T.M. (2001). Transforming growth factor beta1 treatment leads to an epithelial-
mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-
regulated kinase 2 activation. Cancer Res 61, 4222-4228. 
Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, 
A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and 
clinical profiles using the cBioPortal. Science signaling 6, pl1. 
Lieber, M., Mazzetta, J., Nelson-Rees, W., Kaplan, M., and Todaro, G. (1975). Establishment 
of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int 
J Cancer 15, 741-747. 
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408. 
Sporl, F., Schellenberg, K., Blatt, T., Wenck, H., Wittern, K.P., Schrader, A., and Kramer, A. 
(2011). A circadian clock in HaCaT keratinocytes. J Invest Dermatol 131, 338-348. 
Watanabe, M., Sheriff, S., Lewis, K.B., Cho, J., Tinch, S.L., Balasubramaniam, A., and Kennedy, 
M.A. (2012). Metabolic Profiling Comparison of Human Pancreatic Ductal Epithelial Cells and 
Three Pancreatic Cancer Cell Lines using NMR Based Metabonomics. J Mol Biomark Diagn 3, 
S3-002. 
 
